Source: Annual Congress 2011 - Multidrug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
R. Laniado-Laborin, K. Moser, J. Estrada-Guzman, H. Perez (Tijuana, Mexicali, Mexico; San Diego, United States Of America). Successful treatment of multidrug-resistant tuberculosis through a binational consortium. Eur Respir J 2011; 38: Suppl. 55, 398

Member's Comments

No comment yet.

Related content which might interest you: Management and treatment of multidrug-resistant tuberculosis Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management Year: 2019 Treatment outcomes for multidrug-resistant tuberculosis (MDR-TB) patients in Africa Source: Annual Congress 2011 - Multidrug-resistant tuberculosis Year: 2011 Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country Source: Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020 Year: 2021 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Evaluation of treatment outcomes for multidrug-resistant tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001 Tuberculosis in household contacts of multidrug-resistant tuberculosis patients Source: Annual Congress 2011 - Multidrug-resistant tuberculosis Year: 2011 Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003 Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration Source: Eur Respir J 2016; 47: 686-688 Year: 2016 The individual-tailored treatment regimens for multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Transmission of drug-susceptible and drug-resistant mycobacterium tuberculosis among households contacts Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea Source: Eur Respir J, 57 (3) 2003026; 10.1183/13993003.03026-2020 Year: 2021 Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016 Recurrence after successful treatment among patients with multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Medico-surgical considerations when looking for treatment for multidrug-resistant TB Source: Eur Respir J 2002; 20: Suppl. 38, 361s Year: 2002 Surgical approach to multidrug-resistant pulmonary tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 323s Year: 2003 Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007